Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

ESMO open·2026
Same author

Lower Incidence of Dementia Following Cancer Diagnoses: Evidence from a Large Cohort and Mendelian Randomization Study.

The journal of prevention of Alzheimer's disease·2024
Same author

HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

bioRxiv : the preprint server for biology·2024
Same author

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

The journal of prevention of Alzheimer's disease·2024
Same author

Capturing the smile: Exploring embodied and social acts of smiling.

Sociology of health & illness·2024
Same author

Editorial: Dietary Cholesterol and Dementia Risk.

The journal of prevention of Alzheimer's disease·2023

Related Experiment Video

Updated: Jul 3, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

PINK1 mutations and parkinsonism.

L Ishihara-Paul1, M M Hulihan, J Kachergus

  • 1Research and Development, GlaxoSmithKline Pharmaceuticals, Harlow, Greenford, Hammersmith, UK.

Neurology
|August 8, 2008
PubMed
Summary
This summary is machine-generated.

Four pathogenic PINK1 mutations cause early-onset parkinsonism. This study assessed PINK1 mutation frequency in Tunisian families and idiopathic Parkinson disease patients, finding no evidence that PINK1 heterozygosity increases disease risk.

More Related Videos

Measurement of Oxygen Consumption Rate in Acute Striatal Slices from Adult Mice
07:41

Measurement of Oxygen Consumption Rate in Acute Striatal Slices from Adult Mice

Published on: June 8, 2022

Related Experiment Videos

Last Updated: Jul 3, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Measurement of Oxygen Consumption Rate in Acute Striatal Slices from Adult Mice
07:41

Measurement of Oxygen Consumption Rate in Acute Striatal Slices from Adult Mice

Published on: June 8, 2022

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Loss-of-function mutations in the PTEN-induced kinase 1 (PINK1) gene are a known cause of recessive, early-onset parkinsonism.
  • Consanguineous marriage rates are high in Tunisia, necessitating an assessment of PINK1 carrier frequency and disease prevalence in this population.

Purpose of the Study:

  • To determine the frequency of PINK1 mutations in familial parkinsonism, community-based idiopathic Parkinson disease (PD) patients, and control subjects in Tunisia.
  • To compare demographic and clinical characteristics of individuals with and without PINK1 mutations.

Main Methods:

  • Recruitment of 92 kindreds (208 affected, 340 unaffected), 240 nonfamilial PD patients, and 368 controls from the Institut National de Neurologie, Tunis.
  • Clinical assessments using Hoehn &Yahr, UPDRS, and Epworth scales.
  • PINK1 sequencing and dosage analysis, with screening of identified variants in all subjects. Parkin and LRRK2 genes were also examined.

Main Results:

  • Four homozygous PINK1 mutations (three novel: Q129X, Q129fsX157, G440E; one previously reported: Q456X) segregated with parkinsonism in 15% of families (46 individuals).
  • Homozygous Q456X or Q129X substitutions were found in 2.5% of nonfamilial PD patients.
  • PINK1 homozygotes with familial disease exhibited younger onset (36 ± 12 years) than noncarriers (57 ± 15 years), with an akinetic-rigid presentation and slow progression.

Conclusions:

  • Segregation analysis and population frequency estimates suggest only four identified PINK1 mutations are pathogenic.
  • Several PINK1 sequence variants appear benign.
  • No evidence indicates that PINK1 heterozygosity increases susceptibility to idiopathic Parkinson disease.